{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:20:48Z","timestamp":1782307248832,"version":"3.54.5"},"reference-count":44,"publisher":"Journal of Biomedical Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Biomed Res"],"published-print":{"date-parts":[[2026]]},"DOI":"10.7555\/jbr.39.20250259","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T01:53:58Z","timestamp":1762739638000},"page":"210","source":"Crossref","is-referenced-by-count":3,"title":["Isolation of neutralizing antibodies against SARS-CoV-2 through an epitope-guided negative screening by phage display"],"prefix":"10.7555","volume":"40","author":[{"given":"Ming","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4380","reference":[{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.1","doi-asserted-by":"publisher","unstructured":"Weiner LM, Surana R, Wang S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy[J]. <i>Nat Rev Immunol<\/i>, 2010, 10(5): 317\u2013327.","DOI":"10.1038\/nri2744"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.2","doi-asserted-by":"publisher","unstructured":"Paul S, Konig MF, Pardoll DM, et al. Cancer therapy with antibodies[J]. <i>Nat Rev Cancer<\/i>, 2024, 24(6): 399\u2013426.","DOI":"10.1038\/s41568-024-00690-x"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.3","doi-asserted-by":"publisher","unstructured":"Wells TJ, Esposito T, Henderson IR, et al. Mechanisms of antibody-dependent enhancement of infectious disease[J]. <i>Nat Rev Immunol<\/i>, 2024, 25(1): 6\u201321.","DOI":"10.1038\/s41577-024-01067-9"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.4","doi-asserted-by":"publisher","unstructured":"Chen Y, Zhao X, Zhou H, et al. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses[J]. <i>Nat Rev Immunol<\/i>, 2023, 23(3): 189\u2013199.","DOI":"10.1038\/s41577-022-00784-3"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.5","doi-asserted-by":"publisher","unstructured":"McEwan WA, James LC. TRIM21-dependent intracellular antibody neutralization of virus infection[J]. <i>Prog Mol Biol Transl Sci<\/i>, 2015, 129: 167\u2013187.","DOI":"10.1016\/bs.pmbts.2014.10.006"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.6","doi-asserted-by":"publisher","unstructured":"Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19[J]. <i>Cell<\/i>, 2021, 184(4): 861\u2013880.","DOI":"10.1016\/j.cell.2021.01.007"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.7","doi-asserted-by":"publisher","unstructured":"Chia WN, Tan CW, Tan AWK, et al. Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor[J]. <i>Sci Adv<\/i>, 2023, 9(30): eade3470.","DOI":"10.1126\/sciadv.ade3470"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.8","doi-asserted-by":"publisher","unstructured":"Winter G, Milstein C. Man-made antibodies[J]. <i>Nature<\/i>, 1991, 349(6307): 293\u2013299.","DOI":"10.1038\/349293a0"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.9","doi-asserted-by":"publisher","unstructured":"Weiner GJ. Building better monoclonal antibody-based therapeutics[J]. <i>Nat Rev Cancer<\/i>, 2015, 15(6): 361\u2013370.","DOI":"10.1038\/nrc3930"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.10","doi-asserted-by":"publisher","unstructured":"Ho M. Inaugural editorial: Searching for magic bullets[J]. <i>Antib Ther<\/i>, 2018, 1(1): 1\u20135.","DOI":"10.1093\/abt\/tby001"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.11","doi-asserted-by":"publisher","unstructured":"Carter P. Improving the efficacy of antibody-based cancer therapies[J]. <i>Nat Rev Cancer<\/i>, 2001, 1(2): 118\u2013129.","DOI":"10.1038\/35101072"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.12","doi-asserted-by":"publisher","unstructured":"Phakham T, Boonkrai C, Wongtangprasert T, et al. Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development[J]. <i>Sci Rep<\/i>, 2022, 12(1): 17792.","DOI":"10.1038\/s41598-022-20560-6"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.13","doi-asserted-by":"publisher","unstructured":"Lad L, Clancy S, Kovalenko M, et al. High-throughput kinetic screening of hybridomas to identify high-affinity antibodies using bio-layer interferometry[J]. <i>J Biomol Screen<\/i>, 2015, 20(4): 498\u2013507.","DOI":"10.1177\/1087057114560123"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.14","unstructured":"Chen Z, Zhang P, Matsuoka Y, et al. Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants[EB\/OL]. (2022-01-12)[2025-06-10]. https:\/\/www.medrxiv.org\/content\/10.1101\/2022.01.12.22269023v1."},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.15","doi-asserted-by":"publisher","unstructured":"Alassiri M, Lai J, Ch'ng ACW, et al. Subtractive panning for the isolation of monoclonal PEPITEM peptide antibody by phage display[J]. <i>Sci Rep<\/i>, 2023, 13(1): 13627.","DOI":"10.1038\/s41598-023-40630-7"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.16","doi-asserted-by":"publisher","unstructured":"Wellner A, McMahon C, Gilman MSA, et al. Rapid generation of potent antibodies by autonomous hypermutation in yeast[J]. <i>Nat Chem Biol<\/i>, 2021, 17(10): 1057\u20131064.","DOI":"10.1038\/s41589-021-00832-4"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.17","doi-asserted-by":"publisher","unstructured":"Fischer K, Lulla A, So TY, et al. Rapid discovery of monoclonal antibodies by microfluidics-enabled FACS of single pathogen-specific antibody-secreting cells[J]. <i>Nat Biotechnol<\/i>, 2025, 43(6): 960\u2013670.","DOI":"10.1038\/s41587-024-02346-5"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.18","doi-asserted-by":"publisher","unstructured":"Schardt JS, Pornnoppadol G, Desai AA, et al. Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies <i>via<\/i> single B cell screening[J]. <i>Sci Rep<\/i>, 2021, 11(1): 20738.","DOI":"10.1038\/s41598-021-99401-x"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.19","doi-asserted-by":"publisher","unstructured":"Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape[J]. <i>Nat Rev Microbiol<\/i>, 2021, 19(7): 409\u2013424.","DOI":"10.1038\/s41579-021-00573-0"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.20","doi-asserted-by":"publisher","unstructured":"Yuan M, Zhu X, He WT, et al. A broad and potent neutralization epitope in SARS-related coronaviruses[J]. <i>Proc Natl Acad Sci U S A<\/i>, 2022, 119(29): e2205784119.","DOI":"10.1073\/pnas.2205784119"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.21","doi-asserted-by":"publisher","unstructured":"Barderas R, Benito-Pe\u00f1a E. The 2018 Nobel Prize in Chemistry: Phage display of peptides and antibodies[J]. <i>Anal Bioanal Chem<\/i>, 2019, 411(12): 2475\u20132479.","DOI":"10.1007\/s00216-019-01714-4"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.22","doi-asserted-by":"publisher","unstructured":"Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J]. <i>Science<\/i>, 2020, 367(6483): 1260\u20131263.","DOI":"10.1126\/science.abb2507"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.23","doi-asserted-by":"publisher","unstructured":"Oostindie SC, Lazar GA, Schuurman J, et al. Avidity in antibody effector functions and biotherapeutic drug design[J]. <i>Nat Rev Drug Discov<\/i>, 2022, 21(10): 715\u2013735.","DOI":"10.1038\/s41573-022-00501-8"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.24","doi-asserted-by":"publisher","unstructured":"Choudhury A, Mukherjee S. <i>In silico<\/i> studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs[J]. <i>J Med Virol<\/i>, 2020, 92(10): 2105\u20132113.","DOI":"10.1002\/jmv.25987"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.25","doi-asserted-by":"publisher","unstructured":"Choudhury A, Das NC, Patra R, et al. <i>In silico<\/i> analyses on the comparative sensing of SARS-CoV-2 mRNA by the intracellular TLRs of humans[J]. <i>J Med Virol<\/i>, 2021, 93(4): 2476\u20132486.","DOI":"10.1002\/jmv.26776"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.26","doi-asserted-by":"publisher","unstructured":"Choudhury A, Mukherjee G, Mukherjee S. Chemotherapy <i>vs<\/i>. Immunotherapy in combating nCOVID19: An update[J]. <i>Hum Immunol<\/i>, 2021, 82(9): 649\u2013658.","DOI":"10.1016\/j.humimm.2021.05.001"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.27","doi-asserted-by":"publisher","unstructured":"Jiang J, Boughter CT, Ahmad J, et al. SARS-CoV-2 antibodies recognize 23 distinct epitopic sites on the receptor binding domain[J]. <i>Commun Biol<\/i>, 2023, 6(1): 953.","DOI":"10.1038\/s42003-023-05332-w"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.28","doi-asserted-by":"publisher","unstructured":"Li L, Han P, Huang B, et al. Broader-species receptor binding and structural bases of Omicron SARS-CoV-2 to both mouse and palm-civet ACE2s[J]. <i>Cell Discov<\/i>, 2022, 8(1): 65.","DOI":"10.1038\/s41421-022-00431-0"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.29","doi-asserted-by":"publisher","unstructured":"Zhou P, Yang X, Wang X, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. <i>Nature<\/i>, 2020, 579(7798): 270\u2013273.","DOI":"10.1038\/s41586-020-2012-7"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.30","doi-asserted-by":"publisher","unstructured":"Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding[J]. <i>Lancet<\/i>, 2020, 395(10224): 565\u2013574.","DOI":"10.1016\/S0140-6736(20)30251-8"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.31","doi-asserted-by":"publisher","unstructured":"Isobe A, Arai Y, Kuroda D, et al. ACE2 <i>N<\/i>-glycosylation modulates interactions with SARS-CoV-2 spike protein in a site-specific manner[J]. <i>Commun Biol<\/i>, 2022, 5(1): 1188.","DOI":"10.1038\/s42003-022-04170-6"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.32","doi-asserted-by":"publisher","unstructured":"Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein[J]. <i>Cell<\/i>, 2020, 181(2): 281\u2013292.e6.","DOI":"10.1016\/j.cell.2020.02.058"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.33","doi-asserted-by":"publisher","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. <i>Cell<\/i>, 2020, 181(2): 271\u2013280.e8.","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.34","doi-asserted-by":"publisher","unstructured":"Klein C, Brinkmann U, Reichert JM, et al. The present and future of bispecific antibodies for cancer therapy[J]. <i>Nat Rev Drug Discov<\/i>, 2024, 23(4): 301\u2013319.","DOI":"10.1038\/s41573-024-00896-6"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.35","doi-asserted-by":"publisher","unstructured":"Almagro JC, Pedraza-Escalona M, Arrieta HI, et al. Phage display libraries for antibody therapeutic discovery and development[J]. <i>Antibodies (Basel)<\/i>, 2019, 8(3): 44.","DOI":"10.3390\/antib8030044"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.36","doi-asserted-by":"publisher","unstructured":"Wu D, Cong J, Wei J, et al. A na\u00efve phage display library-derived nanobody neutralizes SARS-CoV-2 and three variants of concern[J]. <i>Int J Nanomedicine<\/i>, 2023, 18: 5781\u20135795.","DOI":"10.2147\/IJN.S427990"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.37","doi-asserted-by":"publisher","unstructured":"Dewaker V, Morya VK, Kim YH, et al. Revolutionizing oncology: The role of artificial intelligence (AI) as an antibody design, and optimization tools[J]. <i>Biomark Res<\/i>, 2025, 13(1): 52.","DOI":"10.1186\/s40364-025-00764-4"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.38","doi-asserted-by":"publisher","unstructured":"Huo L, Tian T, Xu Y, et al. Computational nanobody design through deep generative modeling and epitope landscape profiling[J]. <i>Comput Struct Biotechnol J<\/i>, 2025, 27: 3443\u20133455.","DOI":"10.1016\/j.csbj.2025.07.052"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.39","doi-asserted-by":"publisher","unstructured":"Li J, Kang G, Wang J, et al. Affinity maturation of antibody fragments: A review encompassing the development from random approaches to computational rational optimization[J]. <i>Int J Biol Macromol<\/i>, 2023, 247: 125733.","DOI":"10.1016\/j.ijbiomac.2023.125733"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.40","doi-asserted-by":"publisher","unstructured":"Kim J, Mcfee M, Fang Q, et al. Computational and artificial intelligence-based methods for antibody development[J]. <i>Trends Pharmacol Sci<\/i>, 2023, 44(3): 175\u2013189.","DOI":"10.1016\/j.tips.2022.12.005"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.41","doi-asserted-by":"publisher","unstructured":"De Cae S, Van Molle I, Van Schie L, et al. Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base[J]. <i>Nat Commun<\/i>, 2025, 16(1): 5040.","DOI":"10.1038\/s41467-025-60250-1"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.42","doi-asserted-by":"publisher","unstructured":"Norman RA, Ambrosetti F, Bonvin AMJJ, et al. Computational approaches to therapeutic antibody design: Established methods and emerging trends[J]. <i>Brief Bioinform<\/i>, 2020, 21(5): 1549\u20131567.","DOI":"10.1093\/bib\/bbz095"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.43","doi-asserted-by":"publisher","unstructured":"Das NC, Chakraborty P, Bayry J, et al. <i>In silico<\/i> analyses on the comparative potential of therapeutic human monoclonal antibodies against newly emerged SARS-CoV-2 variants bearing mutant spike protein[J]. <i>Front Immunol<\/i>, 2022, 12: 782506.","DOI":"10.3389\/fimmu.2021.782506"},{"key":"10.7555\/JBR.39.20250259.swyxyjzzywb.44","doi-asserted-by":"publisher","unstructured":"Das NC, Chakraborty P, Bayry J, et al. Comparative binding ability of human monoclonal antibodies against omicron variants of SARS-CoV-2: An <i>in silico<\/i> investigation[J]. <i>Antibodies (Basel)<\/i>, 2023, 12(1): 17.","DOI":"10.3390\/antib12010017"}],"container-title":["Journal of Biomedical Research"],"original-title":[],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:49:41Z","timestamp":1775094581000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jbr-pub.org.cn\/article\/doi\/10.7555\/JBR.39.20250259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"alternative-id":["JBR-2025-0259"],"URL":"https:\/\/doi.org\/10.7555\/jbr.39.20250259","relation":{},"ISSN":["1674-8301","1674-8301"],"issn-type":[{"value":"1674-8301","type":"print"},{"value":"1674-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}